HOWL Stock Overview
A biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Werewolf Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.97 |
| 52 Week High | US$8.19 |
| 52 Week Low | US$1.58 |
| Beta | 0.41 |
| 11 Month Change | -33.45% |
| 3 Month Change | -11.26% |
| 1 Year Change | -23.35% |
| 33 Year Change | -85.62% |
| 5 Year Change | n/a |
| Change since IPO | -87.76% |
Recent News & Updates
Recent updates
Werewolf Therapeutics (NASDAQ:HOWL) Has Debt But No Earnings; Should You Worry?
Nov 14
Is Werewolf Therapeutics (NASDAQ:HOWL) Using Debt Sensibly?
Jul 31Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1
Jul 01Some Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Shareholders Look For Exit As Shares Take 34% Pounding
Jun 04Werewolf Therapeutics: In The Hunt For Success In The Cytokine Space
Apr 04Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Feb 07Is Werewolf Therapeutics (NASDAQ:HOWL) A Risky Investment?
Jan 19There's No Escaping Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) Muted Revenues Despite A 28% Share Price Rise
Dec 09Analysts Just Shipped A Captivating Upgrade To Their Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Estimates
Sep 30Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year
Aug 13We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
May 06Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Jan 27We're Not Very Worried About Werewolf Therapeutics' (NASDAQ:HOWL) Cash Burn Rate
Oct 24We're Hopeful That Werewolf Therapeutics (NASDAQ:HOWL) Will Use Its Cash Wisely
Jul 08Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Mar 24Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans
Dec 09Shareholder Returns
| HOWL | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 20.1% | 4.3% | 1.6% |
| 1Y | -23.3% | 18.8% | 32.3% |
Return vs Industry: HOWL underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: HOWL underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| HOWL volatility | |
|---|---|
| HOWL Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HOWL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HOWL's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 45 | Dan Hicklin | werewolftx.com |
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma.
Werewolf Therapeutics, Inc. Fundamentals Summary
| HOWL fundamental statistics | |
|---|---|
| Market cap | US$87.34m |
| Earnings (TTM) | -US$62.12m |
| Revenue (TTM) | US$3.39m |
25.9x
P/S Ratio-1.4x
P/E RatioIs HOWL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HOWL income statement (TTM) | |
|---|---|
| Revenue | US$3.39m |
| Cost of Revenue | US$47.49m |
| Gross Profit | -US$44.10m |
| Other Expenses | US$18.02m |
| Earnings | -US$62.12m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.39 |
| Gross Margin | -1,302.42% |
| Net Profit Margin | -1,834.55% |
| Debt/Equity Ratio | 28.7% |
How did HOWL perform over the long term?
See historical performance and comparison